Table 3.

Drug-resistant rates (%) of carbapenem-resistant, quinolone-resistant, third-generation cephalosporin-resistant E. coli, K. pneumoniae and P. aeruginosa between 2016 and 2019 (n/%)

	E. coli			K. pneumoniae			P. aeruginosa
	Carbapenem - resistant (n = 12)	Quinolone - resistant (n = 161)	Third generation cephalosporin - resistant (n = 150)	Carbapenem - resistant (n = 49)	Quinolone - resistant (n = 69)	Third generation cephalosporin - resistant (n = 30)	Carbapenem - resistant (n = 46)	Quinolone - resistant (n = 41)	Third generation cephalosporin - resistant (n = 12)
AMK	4 (33.3%)	7 (4.3%)	3 (2.0%)	28 (57.1%)	29 (42.0%)	2 (6.7%)	14 (30.4%)	10 (24.4%)	0 (0.0%)
ATM	11 (91.7%)	98 (60.9%)	113 (75.3%)	47 (95.9%)	61 (88.4%)	19 (63.3%)	31 (67.4%)	33 (80.5%)	11 (91.7%)
CAZ	9 (75.0%)	69 (42.9%)	79 (52.7%)	45 (91.8%)	59 (85.5%)	18 (60.0%)	27 (58.7%)	25 (61.0%)	12 (100.0%)
COL	3 (25.0%)	10 (6.2%)	7 (4.7%)	4 (8.2%)	7 (10.1%)	4 (13.3%)	5 (10.9%)	4 (9.8%)	1 (8.3%)
CRO	12 (100.0%)	117 (72.7%)	150 (100.0%)	49 (100.0%)	65 (94.2%)	27 (90.0%)	N	N	N
ETP	12 (100.0%)	9 (5.6%)	0 (0.0%)	49 (100.0%)	45 (65.2%)	0 (0.0%)	N	N	N
FEP	9 (75.0%)	94 (58.4%)	118 (78.7%)	45 (91.8%)	58 (84.1%)	18 (60.0%)	30 (65.2%)	25 (61.0%)	7 (58.3%)
FOX	11 (91.7%)	31 (19.3%)	21 (14.0%)	49 (100.0%)	58 (84.1%)	14 (46.7%)	N	N	N
IPM	8 (66.7%)	8 (5.0%)	0 (0.0%)	44 (89.8%)	43 (62.3%)	0 (0.0%)	44 (95.7%)	25 (61.0%)	0 (0.0%)
LVX	9 (75.0%)	161 (100.0%)	108 (72.0%)	45 (91.8%)	69 (100.0%)	21 (70.0%)	27 (58.7%)	41 (100.0%)	6 (50.0%)
MEM	9 (75.0%)	9 (5.6%)	0 (0.0%)	43 (87.8%)	43 (62.3%)	0 (0.0%)	40 (87.0%)	27 (65.9%)	0 (0.0%)
TOB	-	-	-	-	-	-	7 (28.0%)	6 (26.1%)	0 (0.0%)
TZP	9 (75.0%)	22 (13.7%)	15 (10.0%)	45 (91.8%)	48 (69.6%)	4 (13.3%)	32 (69.6%)	26 (63.4%)	9 (75.0%)

N natural drug resistance; -, no detection

Abbreviations: AMK amikacin, ATM aztreonam, CAZ ceftazidime, COL colistin, CRO ceftriaxone, ETP ertapenem,FEP cefepime, FOX cefoxitin, IPM imipenem, LVX levofloxacin, MEM meropenem, TOB tobramycin, TZP piperacillin-tazobactam